The company collaborated to evaluate Eli Lilly’s ERAS-601 (SHP2 inhibitor) in an ongoing P-I/IIb (FLAGSHP-1) PoC trial as monothx. and in combinations with Erbitux (cetuximab) in patients with triple wildtype (KRAS/NRAS/BRAF wildtype), metastatic CRC and HPV advanced HNSCC
The study will be sponsored by Erasca. Lilly is supplying cetuximab at no cost. Erasca signed CTCSAs with Lilly and Pfizer to evaluate cetuximab and Braftovi (encorafenib) in combination with Erasca’s ERAS-007 (ERK1/2 inhibitor) in the P-Ib/II (HERKULES-3) trial
Additionally, ERAS-601 + cetuximab improved anti-proliferative efficacy and reduced tumor growth compared to either treatment alone in models of HPV- HNSCC and triple wildtype CRC
Ref: GlobalNewswire | Image: Erasca
